Research programme: SARS-coronavirus antibodies - Diversa
Latest Information Update: 16 Jul 2016
At a glance
- Originator Diversa
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Coronavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Parenteral)
- 14 Sep 2004 Preclinical trials in Coronavirus infections in USA (unspecified route)